Occurx
OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis.Occurx
OccuRx Pty Ltd is a start-up company from the University of Melbourne that is developing new drugs that treat the cause of blindness that occurs in some diabetics. Diabetic eye disease includes the development of diabetic retinopathy, cataract (clouding of the lens) and glaucoma (increase ocular fluid pressure leading to optic nerve damage), which can cause severe vision loss and blindness. Diabetic retinopathy is the leading cause of new blindness in persons aged 25-74 in the United States and approximately 700,000 persons in the US have proliferative diabetic retinopathy, with an annual incidence of 65,000. Current treatments cannot restore lost vision and there is a need for new treatments that can control the disease. OccuRx’s lead compounds have been shown to be effective in animal models of fibrosis and diabetic eye disease and the company is progressing its lead drug into phase 1 clinical trials.
Blog Posts
16th September, 2024
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Melbourne, Australia 16 September 2024: Certa Therapeutics (Certa), a biotechnology company developi...
22nd July, 2024
Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic Treatment for Systemic Sclerosis
Melbourne, Australia 22 July 2024: Certa Therapeutics (Certa), a biotechnology company developing in...
19th February, 2024
Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis
Melbourne, Australia 19 February 2024: Certa Therapeutics (Certa), a biotechnology company developin...
15th November, 2023
Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
Melbourne, Australia: 16 November 2023 – Certa Therapeutics (Certa), a biotechnology company develop...
24th October, 2023
Certa Therapeutics’ FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
Melbourne, Australia: 23 October 2023- Certa Therapeutics (Certa), a biotechnology company developin...
5th June, 2023
OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in Boston
Melbourne, Australia, 05 June 2023: OccuRx, a biotechnology company focused on improving lives by de...
5th June, 2023
Certa Therapeutics represented at Biotechnology Innovation Organisation (BIO) International Convention in Boston
Melbourne, Australia, 05 June 2023: Certa Therapeutics, a biotechnology company focused on improving...
17th March, 2023
Listen to Professor Darren Kelly’s interview with Dr Moira Gunn for her TechNation Radio Podcast
Melbourne, Australia: Certa Therapeutics’ founder and CEO, Professor Darren Kelly, had the privilege...
9th March, 2023
Celebrate World Kidney Day and Show your Kidneys some love.
Melbourne, Australia, 9 March 2023: OccuRx, a biotechnology company focused on improving lives by de...
6th February, 2023
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Melbourne, Australia: Certa Therapeutics (Certa) today announces ground-breaking clinical trial data...